We studied the incorporation and metabolism of eicosapentaenoic (EPA) and docosahexaenoic acid in six human volunteers who supplemented their normal Western diet for 5 mo daily with 10-40 ml of cod liver oil, rich in w-3 polyunsaturated fatty acids. EPA and docosahexaenoic acid were incorporated into the total phospholipids of plasma, platelets, and erythrocytes in a doseand time-dependent manner. During w-3 fatty acid ingestion serum triacylglycerols were lowered and platelet aggregation upon low doses of collagen was reduced. Concomitantly, formation and excretion of prostanoids showed a characteristic change. As measured in serum from whole clotted blood, thromboxane A3 was formed in small amounts, whereas thromboxane A2 formation was reduced to 50% of control values. Excretion of the main urinary thromboxane A metabolites was unaltered in subjects with low basal excretion rates, but decreased markedly in two subjects with high control values. As determined from the main urinary metabolite, prostaglandin I3 was formed from EPA at rates up to 50% of unaltered prostaglandin l2 formation. The biochemical and functional changes observed lasted for the entire supplementation period of 5 mo and were reversible within 12 wk after cessation of cod liver oil intake. Favorable changes induced by long-chain w-3 fatty acids include a dose-related and sustained shift of the prostaglandin I/thromboxane A balance to a more antiaggregatory and vasodilatory state.
Introduction
The low incidence of atherosclerotic and chronic inflammatory diseases in Eskimos native to Greenland (1) has been attributed to their traditional diet consisting almost exclusively of marine food, rich in the two w-3 fatty acids eicosapentaenoic acid (EPA)' and docosahexaenoic acid (2) . Furthermore, during supplementation of an otherwise unchanged Western diet with w-3 fatty acids, a favorable pattern of serum lipids (3) (4) (5) , reduced platelet aggregability (6) (7) (8) , a prolonged bleeding time (8) , and a reduced blood pressure response to pressor hormones (8) have been ob-served in studies with human volunteers. In addition, in animal models, fish oils have been found to reduce the size and sequelae ofexperimental myocardial (9) and cerebral infarction (10), prevent proteinuria and prolong survival in murine lupus (1 1), and retard rat mammary tumor growth (12) .
Arachidonic acid (AA) and EPA are precursors of eicosanoids, which have a broad spectrum of biological activities and have been implicated in the pathogenesis of atherothrombotic and inflammatory processes (13) (14) (15) . In contrast to studies in human endothelial cell cultures (16) , and in rats (17) , dietary EPA is transformed in vivo in humans to prostaglandinI3 (18) , which is as active (19) as the vasodilatory and antiaggregatory prostaglandin 12 (20) , derived from AA. Thromboxane A3, formed in small quantities after dietary EPA in human platelets (21) , in addition to reduced thromboxane A2 production is, however, far less proaggregatory than thromboxane A2 (19, 22) . Formation of the three series prostanoids would therefore be a means to alter favorably the prostaglandin I/thromboxane A balance, which has been claimed to play a role in the pathogenesis of vascular disorders (23) . Reduction of serum cholesterol (3, 4) and triacylglycerol (3, 5) observed in humans after dietary W-3 fatty acids may represent other beneficial effects.
Almost all of the human studies with w-3 fatty acids were short-term studies with doses ranging from 50 mg of EPA per day (24) to 120 g of fish oil per day (up to 40% of the daily caloric intake) (3, 5) . In one study, functional changes disappeared after 3 wk of w-3 fatty acid supplementation, despite sustained biochemical changes (25). In another report, reductions in platelet counts were observed after very high doses (3). Although a clinical study on patients with coronary artery disease showed persistent effects ofa fish oil supplement on serum lipids (26) , it has not been clear whether functional and biochemical changes could be sustained for longer time periods. In addition, the time and dose-related incorporation ofdietary w-3 fatty acids into different blood cells in vivo has not been evaluated. Therefore, we measured the effects of cod liver oil supplementation in various dosages on the fatty acid composition in several compartments and on eicosanoid formation in a long-term study in human volunteers.
Methods
Study design. Six healthy male volunteers (ages 26-36 yr, weight 63-88 kg) were advised to withhold all drugs known to interfere with eicosanoid formation or lipid metabolism during the study period of 40 wk. Cod liver oil (Moller A/S, Oslo, Norway) was ingested in addition to an otherwise unchanged Western diet according to Figs. 1-6: i.e., 4 wk 10 ml, puncture with minimal venous stasis through 19-gauge butterfly sets. Platelets were prepared according to published procedures (27, 28). In short, fresh blood was anticoagulated with 0.15 volume of acid citrate dextrose (85 mM trisodium citrate, 111 mM dextrose, 71 mM citric acid); platelet-rich plasma was prepared by centrifugation (200 g) in the presence of prostaglandin 12(5 ng/ml) to prevent platelet activation and adjusted with autologous platelet poor plasma to a final concentration of 250,000 platelets/Al. In a two-channel aggregometer (Fresenius, Bad Homburg, Federal Republic of Germany) platelets were exposed for 8 min to 0.75 or 0.25 Ag/ml collagen of a single batch (Hormon Chemie, Munich) or saline (as control) 45-60 min after venipuncture. The change of the transmission of light after addition of the aggregating agents was recorded as a percentage, 100% corresponding to a change of0.14 optical density.
Fatty acid analyses. Plasma free fatty acids and fatty acids in phospholipids of plasma, of washed erythrocyte ghosts, and of platelets were extracted, methylated, and quantitatively determined as previously described (6, 29) . Briefly, EDTA-coated tubes were filled with fresh whole blood, briefly shaken, and centrifuged at 3,000 gfor 10 min. Plasma was removed and frozen (-20'C) until analyzed. 2 ml of packed red cells was washed twice in saline, lysed by freeze-thawing twice and addition of 10 vol of H20, and centrifuged twice at 15,000 g. The pellet was resuspended in saline and frozen until analyzed. Platelet-rich plasma was prepared as described above and platelets were washed twice in Tyrode'sHepes-EGTA-glucose buffer containing prostaglandin 12 (5 ng/ml) (27, 28).
Plasma free fatty acids were extracted (30) and methylated in 75 JAl of methanol with diazomethane. Plasma, erythrocyte ghost (31) , and platelet lipids (32) were extracted and phospholipids purified by column chromatography (29) . The fatty acid methyl esters were prepared with methanol/H2SO4 (70°C, 2 h). Fatty acid methyl esters were analyzed by gas liquid chromatography on a Packard 419 gas chromatograph equipped with two glass columns (length 2 m, 3 mm i.d.) packed with 10% SP 2340 on 100-120-mesh Supelcoport (Supelchem, Griesbach). Carrier gas was N2; temperature was programmed at 2°C/min from 150 to 200°C. Peaks were identified by comparison to a known standard mixture of fatty acid methyl esters (Sigma Chemical Co., Munich). The amounts of individual fatty acids were calculated as relative percentage with the evaluated fatty acids set as 100%.
Analysis ofprostaglandin I metabolites. Urinary excretion of 2,3-dinor-6-keto prostaglandin Fl. (prostaglandin I2-M) and ofA I 7-2,3-dinor-6-keto prostaglandin Fl. (prostaglandin I3-M), the major urinary metabolites of endogenously formed prostaglandin 12 and prostaglandin I3, respectively, was analyzed by combined capillary gas chromatographymass spectrometry as described previously (18) . In short, 100 ml ofurine was extracted with a highly specific method (33). The methylester-methoxime-trimethylsilylether derivatives were prepared and analyzed on a Finnigan MAT 44S gas chromatography/mass spectrometry system equipped with a fused silica wall-coated, open tubular capillary column (Carbowax CP 51, length 50 m, 0.23 mm i.d.; Chrompack, L6rrach). Operating conditions were: injection port, 280°C; interface, 270°C; ion source, 200°C; electron impact energy, 80 eV; current of emission, 0.9 mA; electron multiplier voltage, 1.8 kV. For quantification of prostaglandin I3-M, the total excretion of prostaglandin 12-M and prostaglandin 13-M (prostaglandin 12+3-M) was assessed after catalytic hydrogenation ofthe urinary extract containing deuterated prostaglandin I2-M as internal standard. Prostaglandin 13-M was calculated by subtracting the separately measured amount of prostaglandin 12-M from the total amount of hydrogenated prostaglandin 12+3-M ( 18). Analysis ofthromboxaneA metabolites. In serum from clotted whole blood (10 ml, 1 h, 37°C) immunoreactive thromboxane B2/3 (ithromboxane B2/3) was assessed after acidification, extraction, and purification by high performance liquid chromatography as described previously (27, 34). We used a specific thromboxane B2 antiserum (a gift from L. Levine, Brandeis University, Waltham, MA, USA), standard thromboxane B2 (purchased from Upjohn, Kalamazco, MI), and [3H1thromboxane B2
(New England Nuclear, Dreieich, Federal Republic of Germany) with a specific activity of 150 Ci/mmol.
To measure thromboxane B2 and thromboxane B3 separately, lipids of 5 ml ofserum from clotted whole blood were extracted (27), methylated with diazomethane, and purified by thin-layer chromatography with the organic phase of ethylacetate/isooctane/acetic acid/H20 (110:50:20:100).
Thromboxane B2 and thromboxane B3 were eluted with methanol and analyzed as methylester-methoxime-trimethylsilylether derivatives by combined capillary gas chromatography (capable of separating thromboxane B2 and thromboxane B3) mass spectrometry (21) .
The urinary excretion of immunoreactive 2,3-dinor-thromboxane B2/3 in 24 h was assessed as described previously (34) . 30 ml of urine was acidified and extracted, and eicosanoids were fractionated by reverse-phase high performance liquid chromatography. We used [3H]-thromboxane B2 as a tracer and thromboxane B2 antiserum, which had 50-60% cross-reactivity with authentic 2,3-dinor thromboxane B2. Crossreactivity with 2,3-dinor thromboxane B3 could not be assessed due to the lack of authentic standard.
Other analyses. A standardized questionnaire concerning protocol adherence, side effects, and state ofhealth was filled out for each volunteer at each visit.
Serum cholesterol, high density lipoprotein cholesterol (both Boehringer, Mannheim), and triacylglycerol (Merck, Darmstadt) and all other determinations (blood counts and the remaining serum data, and urine data) were performed with routine methods in the central laboratory at our hospital.
Statistics. Data were analyzed by the two-tailed paired t-test on control at week 0 versus the respective time point.
Results
Fatty acid changes in plasma, platelets, and red cells. Plasma free fatty acids (Fig. I a) displayed dose-related changes of EPA and docosahexaenoic acid, with insignificant changes in both linoleic acid and AA. In plasma phospholipids (Fig. I b) , EPA and docosahexaenoic acid increased rapidly in a dose-related manner and linoleic acid and AA decreased, but AA only at the higher doses of cod liver oil. AA, EPA, and linoleic acid returned to control values within 8 wk after cessation of the cod liver oil supplementation. In platelet phospholipids (Fig. I c) EPA and docosahexaenoic acid increased slower than in plasma phospholipid fatty acids, with the decrease of AA accounting almost completely for the exchange. Linoleic acid remained unchanged. Changes in plasma and platelet fatty acid composition reached their extremes with maximum dosing of cod liver oil, at 12 wk. In erythrocyte membranes (Fig. I d) EPA and docosahexaenoic acid were increasing up to week 20, 8 wk after the reduction of the dose of cod liver oil. Docosahexaenoic acid had even not returned to control values 20 wk after cessation of cod liver oil. In plasma, platelet, and erythrocyte phospholipids, the sum of palmitic, stearic, and oleic acid remained constant at between 58 and 68% of the fatty acids throughout the study. In plasma free fatty acids, the sum of these three fatty acids varied insignificantly between 70 and 77%.
Triacylglycerol levels in serum decreased closely related to the dose of cod liver oil, whereas cholesterol and high density lipoprotein cholesterol did not change significantly during the study (Fig. 2) .
Platelet aggregation. Platelet aggregation (Fig. 3 ) in plateletrich plasma upon low doses of collagen (0.25 and 0.75 ,ug/ml) was persistently decreased during the period ofcod liver oil with a nadir at the maximum dosing of cod liver oil, and returned to control values at the end ofthe study. Platelet counts decreased from a control value of 181,000±36,000 to 151,200±26,700 at week 20 (P < 0.05) (see Fig. 6 ).
Eicosanoids. Prostaglandin 13-M, the major urinary metab- decreased quickly and was dose related during cod liver oil supplementation, and had not yet returned to control values 8 wk after cessation ofcod liver oil. Thromboxane B2 concentrations, measured in the same serum samples by gas chromatography/ mass spectrometry, were lower in absolute terms, but paralleled the radioimmunologic determinations (Fig. 6 ). Thromboxane B3 was detectable in small quantities in all samples during cod liver oil, exact quantification however was not possible due to the lack of deuterated standard thromboxane B3. Safety and routine laboratory data included in a standardized questionnaire, heart rate, body weight, complete blood counts, sodium, potassium, calcium, uric acid, kidney and liver function parameters in serum, urinary excretion of sodium, potassium, and calcium, and plasma coagulant activity were unchanged throughout the study. No adverse effects of the intake of cod liver oil were observed; no volunteer became ill during the study. olite of endogenous prostaglandin 13, was detectable in urine only during the intake of cod liver oil. Related to the intake of cod liver oil, prostaglandin 13-M amounted up to 50% of prostaglandin I2-M, the major metabolite of prostaglandin I2. Production of prostaglandin 12 was unaltered throughout the study, as measured by the urinary excretion ofprostaglandin 12-M (Fig.   4) . Excretion of immunoreactive 2,3-dinor thromboxane B2/3 remained unaltered during the study in four volunteers with low control values of 2,3-dinor thromboxane B2, whereas in the two volunteers with high control values (2,310 and 3,266 ng/g creatinine, respectively), it decreased to -25% of control values and returned thereafter to prestudy values (Fig. 5) . Immunoreactive thromboxane B2/3 in serum from clotted whole blood In this long-term study, we evaluated the effects of cod liver oil in various dosages in healthy volunteers. Administration of cod ml/day
Discussion
Figture 6. Platelet count (platelets/Al) in blood and thromboxane formation in serum of clotted whole blood (ng/ml, mean±SEM) before, during, and after intake of dietary cod liver oil (CLO) in various dosages. Thromboxane (TX) B2/3 (n = 6) was measured radioimmunologically (RIA), thromboxane B2 (n = 3) was measured by combined gas chromatography/mass spectrometry (GC-MS). *, P < 0.05, paired t test as compared to time 0.
In vitro an avid incorporation of radioactive AA and EPA and, to a lesser extent, of labeled docosahexaenoic acid into platelet and erythrocyte phospholipids can be observed (38) (39) (40) (41) .
In vivo, however, in spite of considerable amounts of EPA and docosahexaenoic acid in plasma free fatty acids, the fatty acid changes in platelet and, even more so, in erythrocyte phospholipids occurred with delay. In erythrocytes EPA and docosahexaenoic acid continued to increase despite reduction of the dose of cod liver oil. Thus, in vivo in humans only a limited exchange between cellular and plasma AA, EPA, and docosahexaenoic acid may contribute to the actual fatty acid pattern in blood cell phospholipids. In that this exchange is probably the only influence on cellular phospholipid fatty acid composition after cell formation, it may well be that, in this respect, cells are defined to a considerable extent during cell formation.
In phospholipids, polyunsaturated fatty acids are located almost exclusively in the sn-2 position ofthe glycerol moiety (40) , and cw-6 and w-3 polyunsaturated fatty acids compete for the same binding sites. During ingestion of cod liver oil, EPA and docosahexaenoic acid increased in all phospholipids studied; the w-6 fatty acids, however, were not exchanged proportionately. For example, linoleic acid was reduced in plasma and erythrocytes, but was unaffected in platelets. This finding excludes simple competition between the w-6 and w-3 fatty acids for the sn-2 position ofthe glycerol moiety as the only regulatory mechanism. Cholesterol and triglycerides. Cod liver oil reduced in a dosedependent manner triacylglycerol levels in serum to 66% ofcontrol values, indicating, that a 4-8.3 g/day w-3 fatty acid supplement may be sufficient to reduce the synthesis of apoprotein B, as observed in human volunteers with 24 g/day (5). With a maximum dose of 8.3 g of w-3 fatty acids in normocholesterolemic volunteers, a lowering of serum cholesterol, comparable to that in patients with elevated cholesterol levels after far higher doses of w-3 fatty acids (3-5), could not be expected. Nevertheless w-3 fatty acids are as potent as w-6 fatty acids in lowering serum cholesterol levels (3).
Platelet aggregation
Ex vivo platelet aggregation upon low-dose collagen was reduced during cod liver oil. The platelet count decreased, but never went below the physiologic range. Aggregation studies were performed in adjusted platelet-rich plasma (27) using a single batch of collagen. In short-term studies (up to 4 wk) comparable effects were seen (6, 7, 18, 42, 43) , but in a 1 l-wk trial platelet aggregation upon 0.5-4 ,ug/ml collagen returned to normal at 6 wk (25). This may be due to different sources of w-3 fatty acids used (fish or cod liver oil) or to methodologic differences (27, 43). The decrease in platelet aggregation paralleled the increase of w-3 fatty acids and the decrease of AA by -20% in platelet phospholipids. In serum from whole clotted blood thromboxane B2/3, as measured by radioimmunoassay, and thromboxane B2, as measured by gas chromatography/mass spectrometry, were reduced by 50%. In vitro, a ratio AA to EPA of 1:1 is necessary for a 50% inhibition ofcyclooxygenation ofAA (19). Therefore, the reduced concentration of AA in phospholipids cannot be the only limiting step of thromboxane formation. Other mechanisms such as changes in the physicochemical properties of membranes (40) , impaired coupling of collagen to its receptors or differences in the release of AA and EPA from membrane phospholipids (6, 29) may contribute to the reduced aggregation and thromboxane formation.
Eicosanoid synthesis
We estimated eicosanoid biosynthesis via two approaches: (a) measurement ofa specific urinary metabolite, thus assessing the endogenous biosynthesis of the respective eicosanoid and (b) measurement of eicosanoids in maximally stimulated samples ex vivo, thus assessing cellular capacity ofeicosanoid production.
Prostaglandin 13-M, the major urinary metabolite of prostaglandin I3, formed in vivo from ingested EPA, was detected persistently during the intake period for cod liver oil, and increased in a dose-dependent manner with increasing amounts ofcod liver oil. Interestingly, at the same time, endogenous production of prostaglandin I2, as measured by its major urinary metabolite, prostaglandin 12-M, was not reduced. These in vivo results are in contrast to results ofstudies with human endothelial cell cultures, where a reduced prostaglandin 12 production upon stimulation with thrombin was observed after preincubation of the cells with EPA (17) . Animal experiments are not applicable in this respect, because rats do not form prostaglandin I3 after dietary EPA (16) . In vivo in humans, however, the endogenous production of potent antiaggregatory and vasodilatory substances, i.e., the sum of prostaglandin 12 and prostaglandin I3, was increased during EPA in this and in a previous study (18) .
Endogenous thromboxane A2/3 formation, as determined by radioimmunological measurement of urinary 2,3-dinor thromboxane B2/3 excretion, was largely unaltered during the ingestion period of cod liver oil in the four subjects with normal control levels (normal range in our laboratory 485±153 ng/g creatinine, n = 46). The excretion of 2,3-dinor thromboxane B2 was severalfold higher before and after cod liver oil in two subjects, and this high excretion rate decreased during cod liver oil. This may be attributed to reduction of an increased in vivo platelet activation by ingestion ofcod liver oil. In serum from whole clotted blood, the capacity of platelets to form thromboxane A2 was reduced during period of intake of cod liver oil, with a concomitant formation ofthromboxane A3 in small amounts. Formation of thromboxane A3, which is hardly (22) , if at all (2, 19), proaggregatory, has previously been detected after dietary EPA in platelet rich plasma (21) or washed platelets (29) . Thromboxane A2 formation was reduced closely related to the dose ofcod liver oil, as measured by combined gas chromatography/mass spectrometry. As measured by radioimmunoassay in the same samples, thromboxane B2/3 was higher in absolute terms, probably due to unspecific cross-reacting material, but followed the same characteristic pattern. Thus the capacity of platelets to form thromboxane was reduced during the ingestion of cod liver oil.
In experiments with human neutrophils, EPA enrichment by dietary means, and stimulation with Ca++ ionophore resulted in formation of leukotriene B5 in appreciable amounts (44, 45) . Concomitant leukotriene B4 formation was unchanged after 3-4 wk (44, 45) , and decreased after 6 wk (45) . In the present study and in other studies, thromboxane formation of EPA-enriched platelets was reduced upon stimulation ex vivo after less than 6 wk (3, 6, 8) . These data point to differences in handling of EPA between different cells, and to time-dependent changes in cellular response to dietary alterations. The endogenous biosynthesis of thromboxane A2/3 was reduced ifthe controls were elevated, but formation of prostaglandin 12 unchanged with an additional synthesis of prostaglandin 13. Since ex vivo studies on EPAenriched human endothelium have not been performed, it can only be speculated, that such differences pertain also to endothelial cells.
In our study fatty acid changes and prostanoid formation have been found to be different from the results of experiments in vitro or in animals. It seems doubtful, therefore, that in vitro or animal studies with w-3 fatty acids can be directly compared with those carried out after administration of co-3 fatty acids to humans. We conclude, that in humans w-3 fatty acids are incorporated and metabolized with a high degree of specificity. Besides lowering serum lipids, reducing platelet aggregability ex vivo and probably in vivo, and lowering blood pressure and blood vessel reactivity (10), dietary w-3 fatty acids alter the spectrum of eicosanoids in a favorable manner.
